Table 3.

Effects of tamsulosin/zolpidem on nocturia in patients with benign prostatic hyperplasia

		IPSS		QOL		Nocturia episodes		Nocturia QOL		AIS
All (n = 35)	Baseline	18.9 ±3.8	**	4.5 ±0.9	**	3.4 ±0.7	**	5.5 ±0.6	**	11.7 ±3.6	**
	After treatment	9.9 ±3.0		3.2 ±0.9		2.6 ±1.0		4.3 ±1.5		9.1 ±3.1
Group A (n = 15)	Baseline	18.3 ±3.7	**	4.4 ±0.6	**	3.3 ±0.6	**	5.2 ±0.6	**	11.2 ±3.6	**
	After treatment	8.7 ±3.2		2.5 ±0.6		1.7 ±0.5		2.6 ±0.5		7.9 ±3.1
Group B (n = 16)	Baseline	18.9 ±4.1	**	4.6 ±1.0	**	3.4 ±0.9	NS	5.7 ±0.5	NS	12.9 ±3.3	**
	After treatment	10.4 ±2.6		3.8 ±0.6		3.3 ±0.8		5.6 ±0.5		10.6 ±2.9
	After additional treatment	9.3 ±2.6	NS	3.5 ±1.4	NS	1.9 ±0.7	**	3.6 ±1.1	**	6.8 ±2.5	**

IPSS - International Prostate Symptom Score, QOL - quality of life, AIS - Athens Insomnia Scale, All and Group A - Monotherapy with tamsulosin for 4 weeks, Group B - Combination therapy with tamsulosin and zolpidem for 2 weeks, After treatment - after treatment with tamsulosin, After additional treatment - after treatment with tamsulosin and zolpidem.

^**p < 0.001, NS: p ≥0.05 (Wilcoxon signed-rank test)